SPD-754. Shire.
Shire Pharmaceuticals is developing SPD-754 for the potential treatment of HIV infection. Phase I trials had been completed by October 2002, and phase II trials were initiated in December 2002.
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D013329:Structure-Activity Relationship; D013872:Thionucleosides / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome
C120719:2'-deoxy-3'-oxa-thiocytidine; D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D013872:Thionucleosides; D003841:Deoxycytidine; D054303:HIV Reverse Transcriptase